Items where authors include "Hemmings, G"

Article

Ajaib, S, Lodha, D, Pollock, S et al. (14 more authors) (2023) GBMdeconvoluteR accurately infers proportions of neoplastic and immune cell populations from bulk glioblastoma transcriptomics data. Neuro-Oncology. ISSN 1522-8517

Richman, SD orcid.org/0000-0003-3993-5041, Hemmings, G, Roberts, H et al. (12 more authors) (2022) FOCUS4 biomarker laboratories: from the benefits to the practical and logistical issues faced during 6 years of centralised testing. Journal of Clinical Pathology. ISSN 0021-9746

Seligmann, JF, Elliott, F, Richman, S orcid.org/0000-0003-3993-5041 et al. (8 more authors) (2020) Clinical and molecular characteristics and treatment outcomes of advanced right-colon, left-colon and rectal cancers: data from 1180 patients in a phase III trial of panitumumab with an extended biomarker panel. Annals of Oncology, 31 (8). pp. 1021-1029. ISSN 0923-7534

Gollins, S, West, N orcid.org/0000-0002-0346-6709, Sebag-Montefiore, D et al. (17 more authors) (2017) Preoperative chemoradiation with capecitabine, irinotecan and cetuximab in rectal cancer: significance of pre-treatment and post-resection RAS mutations. British Journal of Cancer, 117. pp. 1286-1294. ISSN 0007-0920

Seligmann, JF, Elliott, F, Richman, SD et al. (7 more authors) (2016) Combined Epiregulin and Amphiregulin Expression Levels as a Predictive Biomarker for Panitumumab Therapy Benefit or Lack of Benefit in Patients With RAS Wild-Type Advanced Colorectal Cancer. JAMA oncology, 2 (5). pp. 633-642. ISSN 2374-2437

Richman, SD orcid.org/0000-0003-3993-5041, Southward, K, Chambers, P orcid.org/0000-0002-0926-717X et al. (16 more authors) (2016) HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: Analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. Journal of Pathology, 238 (4). pp. 562-570. ISSN 0022-3417

Richman, SD, Adams, R, Quirke, P et al. (10 more authors) (2016) Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial. Journal of Clinical Pathology, 69 (1). pp. 35-41. ISSN 0021-9746

Conference or Workshop Item

West, NP, Kodavatiganti, R, Hemmings, G et al. (6 more authors) (2015) Pre-Treatment and Post-Treatment Epidermal Growth Factor Receptor Pathway Mutations in a Prospective Phase II Trial (NWCOG EXCITE) of Cetuximab-Containing Chemoradiation in Locally Advanced Rectal Cancer. In: Dublin Pathology 2015: 8th Joint Meeting of the British Division of the International Academy of Pathologyand the Pathological Society of Great Britain & Ireland, 23-25 Jun 2015, Dublin.

Proceedings Paper

Williams, C, Emmerson, J, Beggs, AD et al. (12 more authors) (2022) A biomarker enrichment trial of anti-EGFR agents in right primary tumor location (rPTL), RAS wild-type (RAS-wt) advanced colorectal cancer (aCRC): ARIEL (ISRCTN11061442). In: Journal of Clinical Oncology. 2022 ASCO Annual Meeting, 03-07 Jun 2022, Online & Chicago, IL, USA. American Society of Clinical Oncology .

Taylor, M, Wood, H, Bottomley, D et al. (9 more authors) (2015) Comparison of Mutational Calls Obtained with Pyrosequencing and the Affymetrix OncoScan (R) FFPE Assay in Patients with Colon Cancer Recruited to the NCRI FOxTROT Trial. In: Journal of Pathology. Dublin Pathology 2015: 8th Joint Meeting of the British Division of the International Academy of Pathology and the Pathological Society of Great Britain & Ireland, 23-25 Jun 2015, Dublin, Ireland. Wiley , S39-S39.

Taylor, M, Wood, H, Tinkler-Hundal, E et al. (9 more authors) (2015) Investigating the Challenges of Using Historical Formalin-Fixed Paraffin-Embedded (FFPE) Material from the MRC CR07 Rectal Cancer Trial Using the Affymetrix OncoScan (R) FFPE Assay and Next Generation Sequencing. In: Journal of Pathology. Dublin Pathology 2015: 8th Joint Meeting of the British Division of the International Academy of Pathology and the Pathological Society of Great Britain & Ireland, 23-25 Jun 2015, Dublin, Ireland. Wiley , S38-S38.